A recent study reveals that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who end traditional diet and exercise regimens.
Research printed in a major medical journal points out that while obese individuals often shed about a fifth of their total mass while on the medication, the mass returns at an estimated rate of nearly a kilo each month once they quit.
"People buying these treatments must be informed of the risk of rapid weight regain when the therapy is stopped," stated expert Dr. Susan Jebb.
Such speed of recovery suggests a return to original weight within about a year and a half.
Analyzing Approaches
The research, which reviewed dozens of trials involving over 9,000 of patients, contrasted the results of the injectable medications with conventional dieting.
Scientists emphasize that individuals who lose weight through diet and exercise generally have a slower weight regain—perhaps 0.1 kg a month—post-intervention.
The Reason for the Rapid Regain
Doctors believe the mode of action of the drugs is key to understanding the amplified rebound.
These medications mimic a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 concentrations several times higher than normal might result in the system to generate a reduced amount of its own natural GLP-1, and could reduce responsiveness to its effects," said Dr. Adam Collins, a dietetics expert.
"Withdrawal of this hormone supplement leads to appetite is no longer kept in check, making binge eating far more likely."
A Lifelong Condition?
Health authorities advise the jabs for individuals with obesity-related health risks, accompanied by recommended lifestyle changes.
Many experts argue that, due to the high risk of weight regain, the therapy should be considered ongoing.
This perspective is supported by pharmaceutical companies, who say that the findings "highlight the long-term nature of excess weight," comparing it to managing conditions like diabetes.
User Accounts
People who have stopped the jabs report a sudden return of appetite.
"It felt as if a trigger flipping and you're instantly starving," described one woman.
This difficulty is worsened if individuals have not developed permanent dietary or behavioural modifications during treatment.
Widespread Interest
Figures suggest that millions of adults in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Use is more common among women compared to males.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion obtain the medications through private healthcare rather than public health services.
Ultimately, clinicians stress that while GLP-1 drugs are potent agents for weight loss, they are not a standalone fix and long-term success hinges on combined behavioural support.
